Green Alpha Advisors, LLC Seagen Inc. Transaction History

Green Alpha Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 10, 2023	SELL	$191.51 - $216.16 $103,223 - $116,510	-539 Reduced 20.77%	2,056 $436,000
Q2 2023 Jul 06, 2023	BUY	$187.64 - $206.25 $3,565 - $3,918	19 Added 0.74%	2,595 $499,000
Q1 2023 Apr 06, 2023	SELL	$127.59 - $203.08 $7,272 - $11,575	-57 Reduced 2.16%	2,576 $521,000
Q4 2022 Jan 12, 2023	BUY	$117.37 - $139.17 $22,652 - $26,859	193 Added 7.91%	2,633 $0
Q3 2022 Oct 14, 2022	SELL	$135.27 - $180.11 $1.2 Million - $1.6 Million	-8,902 Reduced 78.49%	2,440 $334,000
Q2 2022 Jul 08, 2022	BUY	$108.81 - $179.33 $870,371 - $1.43 Million	7,999 Added 239.28%	11,342 $2.01 Million
Q1 2022 Apr 19, 2022	SELL	$119.61 - $157.85 $63,154 - $83,344	-528 Reduced 13.64%	3,343 $482,000
Q4 2021 Jan 12, 2022	BUY	$142.57 - $190.86 $4,562 - $6,107	32 Added 0.83%	3,871 $598,000
Q3 2021 Oct 12, 2021	BUY	$142.45 - $169.82 $37,464 - $44,662	263 Added 7.35%	3,839 $652,000
Q2 2021 Jul 22, 2021	BUY	$135.08 - $161.1 $68,215 - $81,355	505 Added 16.44%	3,576 $565,000
Q1 2021 Jul 22, 2021	BUY	$137.51 - $190.8 $215,340 - $298,792	1,566 Added 104.05%	3,071 $426,000
Q4 2020 Jul 22, 2021	BUY	$164.63 - $211.93 $247,768 - $318,954	1,505 New	1,505 $264,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Green Alpha Advisors, LLC with notifications on news.